# Study on Safety and Clinical Efficacy of AZVUDINE in Initial Stage COVID-19 Patients (SARS-CoV-2 Infected)

> **NCT05033145** · PHASE3 · COMPLETED · sponsor: **HRH Pharmaceuticals Limited** · enrollment: 312 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** AZVUDINE
- **DRUG:** AZVUDINE placebo

## Key facts

- **NCT ID:** NCT05033145
- **Lead sponsor:** HRH Pharmaceuticals Limited
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-15
- **Primary completion:** 2022-07-27
- **Final completion:** 2022-07-27
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2022-08-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05033145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05033145, "Study on Safety and Clinical Efficacy of AZVUDINE in Initial Stage COVID-19 Patients (SARS-CoV-2 Infected)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05033145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*